In detail, we investigated the FV Leiden polymorphism, FV R2, prothrombin 20210 G>A, FXIII Val34Leu, beta-fibrinogen −455 G>A, HPA1a/1b, MTHFR 677 C>T, MTHFR 1298 A>T, PAI-1 4G/5G, ACE I/D, and Apo B R3500Q, and, to the best of our knowledge, this is the first study assessing such polymorphisms that may increase the predisposition of thrombotic episodes or cardiovascular events in MS, known pathological conditions in early disease occurrence [33,34]. This evidence concerns the gene F5 and myeloid sarcoma.